These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36828401)

  • 1. A Single-Group Study on the Effect of OnabotulinumtoxinA in Patients with Chronic Migraine Associated with Medication Overuse Headache: Pain Catastrophizing Plays a Role.
    Grazzi L; Montisano DA; Rizzoli P; Guastafierro E; Marcassoli A; Fornari A; Raggi A
    Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A; Curto M; Lionetto L; Martelletti P
    J Headache Pain; 2015; 17():1. PubMed ID: 26792662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study.
    d'Onofrio F; de Falco A; Costanzo A; Spitaleri D; Casucci G; Raimo S
    J Clin Neurosci; 2020 Oct; 80():152-155. PubMed ID: 33099338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Jan; 20(1):10. PubMed ID: 30669961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
    Bendtsen L; Sacco S; Ashina M; Mitsikostas D; Ahmed F; Pozo-Rosich P; Martelletti P
    J Headache Pain; 2018 Sep; 19(1):91. PubMed ID: 30259200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine.
    Martelletti P
    J Headache Pain; 2018 Jan; 19(1):2. PubMed ID: 29322261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic migraine: current concepts and ongoing treatments.
    Negro A; Rocchietti-March M; Fiorillo M; Martelletti P
    Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1401-20. PubMed ID: 22288302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study).
    Grazzi L; D'Amico D; Guastafierro E; Demichelis G; Erbetta A; Fedeli D; Nigri A; Ciusani E; Barbara C; Raggi A
    J Headache Pain; 2023 Jul; 24(1):86. PubMed ID: 37452281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous allodynia and thermal thresholds in chronic migraine: The effect of onabotulinumtoxinA.
    Ozarslan M; Matur Z; Tuzun E; Oge AE
    Clin Neurol Neurosurg; 2022 Sep; 220():107357. PubMed ID: 35792471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
    Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal.
    Andreou AP; Trimboli M; Al-Kaisy A; Murphy M; Palmisani S; Fenech C; Smith T; Lambru G
    Eur J Neurol; 2018 Aug; 25(8):1069-e83. PubMed ID: 29617060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Propensity Score Matching Study on the Effect of OnabotulinumtoxinA Alone versus Short-Term Psychodynamic Psychotherapy Plus Drug-of-Choice as Preventive Therapy in Chronic Migraine: Effects and Predictive Factors.
    Alessiani M; Petolicchio B; De Sanctis R; Squitieri M; Di Giambattista R; Puma M; Franzese C; Toscano M; Derchi CC; Gilliéron E; Viganò A; Di Piero V
    Eur Neurol; 2022; 85(6):453-459. PubMed ID: 35772386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.
    Negro A; Curto M; Lionetto L; Crialesi D; Martelletti P
    Springerplus; 2015; 4():826. PubMed ID: 26753113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.